Listen to article
6:21Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 16 October 2026
Read article
There’s a certain grim satisfaction in watching a rival stumble. In the world of investing, it’s not just about schadenfreude, it’s about opportunity. When the US Food and Drug Administration recently slammed the door on PTC Therapeutics' new drug application, I imagine a few quiet cheers went up in the boardrooms of its competitors. And frankly, as an investor, I can see why. This isn't just one company's bad day at the office. It’s a stark reminder of why the rare disease sector is one of the most fascinating and potentially defensible corners of the market.
Let’s be clear. Getting a drug approved for a rare, or ‘orphan’, disease is a brutal, eye-wateringly expensive affair. You face the same punishing regulatory gauntlet as a company developing a blockbuster for millions, but your target market might be a few thousand people scattered across the globe. When a would-be competitor spends a decade and hundreds of millions of pounds only to fail at the final hurdle, it does more than just remove a rival from the field. It reinforces the enormous walls protecting the companies already inside the castle.
To me, this is the crux of the matter. Companies like Ultragenyx Pharmaceutical have built their entire empires on this principle. They operate in niche markets where competition is, by its very nature, scarce. Each successful drug they get to market is like a tiny, protected monopoly. The recent failure of a potential competitor doesn't just maintain the status quo, it actively strengthens their position, making their existing revenue streams look even more secure.
It sounds mad, doesn't it? Building a business model around having as few customers as possible. But the economics of orphan drugs are wonderfully counterintuitive. Think of it like this, you can either sell millions of Ford Fiestas at a tight margin, or you can sell a handful of bespoke Rolls-Royces for a fortune. Companies like SpringWorks Therapeutics are firmly in the Rolls-Royce camp.
Because their treatments are often the only hope for patients with devastating conditions, they can command premium prices. Insurers and health systems are more willing to pay up when there is no alternative. This creates a business with potentially higher margins and more predictable revenues than its mass-market cousins. Every time a new entrant fails to get approval, that period of premium pricing and market dominance for the incumbent gets a little bit longer. It’s a simple, if rather ruthless, equation.
So, where does this leave the savvy investor looking for a bit of shelter in the turbulent pharmaceutical seas? Well, it points towards the value of a well-built moat. The regulatory expertise and sheer capital required to succeed in this space are not easily replicated. It’s a club with a very strict door policy, and every failed application just makes the bouncer bigger. For established players like Amicus Therapeutics, a competitor’s rejection is validation of their strategy and a signal to the market that their fortress is secure.
This is the dynamic that underpins investment ideas like the Orphan Drug Moats: Leaders In Rare Disease basket, which focuses on precisely these kinds of companies. The investment thesis isn't just about the science, it's about the formidable barriers to entry that protect profits. It’s a recognition that in this particular game, the failure of others can be a powerful, long-term tailwind for the established winners.
View the full Basket:Orphan Drug Moats: Leaders In Rare Disease
View the full Basket:Orphan Drug Moats: Leaders In Rare Disease
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 17 October 2026
Read article
Published on 16 October 2026
Read article
